Clinical heterogeneity, unpredictable course and flares are characteristics of systemic lupus
erythematosus (SLE). Although SLE is—by and large—a systemic disease, occasionally it …

The treat-to-target (T2T) concept has improved outcomes for patients with diabetes,
hypertension and rheumatoid arthritis. This therapeutic strategy involves choosing a well …

Objective To develop recommendations for cardiovascular risk (CVR) management in gout,
vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD) …

Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

Abstract Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic and
no antiviral drug or vaccine is yet available for the treatment of this disease,–. Several …

Objective To assess the efficacy and safety of the type I interferon receptor antibody,
anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This …

Lupus nephritis (LN) is a frequent and severe manifestation of SLE. Along the decades, the
epidemiology of LN and its clinical presentation have been changing. However, even …

We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis
(BLISS-LN), a Phase 3, multinational, double-blind, 104-week trial, in which 448 patients …

The antimalarial hydroxychloroquine (HCQ) has demonstrated several crucial properties for
the treatment of systemic lupus erythematosus (SLE). Herein, we reviewed the main HCQ …

Objective AURORA 2 evaluated the long‐term safety, tolerability, and efficacy of voclosporin
compared to placebo in patients with lupus nephritis (LN) receiving an additional two years …